Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 8/20 | 0.48 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.48 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5028839 | 0.88 | CYP3A4 (0.44) | LPAR3LPAR2LPAR1CYP3A4TSHR | |
| SCHEMBL28395754 | 0.83 | CYP3A4 (0.40) | LPAR3LPAR2LPAR1CYP3A4S1PR2 | |
| SCHEMBL787793 | 0.81 | CYP3A4 (0.48) | LPAR3LPAR2LPAR1CYP3A4TSHR | |
| SCHEMBL814225 | 0.81 | CYP3A4 (0.48) | LPAR3LPAR2LPAR1CYP3A4S1PR2 | |
| SCHEMBL98778 | 0.81 | PPARD (0.38) | LPAR3LPAR2LPAR1CYP3A4TSHR | |
| SCHEMBL4267679 | 0.80 | CYP3A4 (0.47) | LPAR3LPAR2LPAR1CYP3A4S1PR2 | |
| SCHEMBL5028888 | 0.76 | FDPS (0.36) | LPAR3LPAR2LPAR1CYP3A4S1PR2 | |
| SCHEMBL3896487 | 0.75 | GRM2 (0.32) | — | |
| SCHEMBL5028805 | 0.75 | CYP3A4 (0.41) | LPAR3LPAR2LPAR1CYP3A4TSHR | |
| SCHEMBL28747383 | 0.74 | LPAR3 (0.82) | LPAR3LPAR2LPAR1CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-1939205-A1 | TRICYCLIC COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | FDFT1, COASY, HMGCR | LPAR3 511/4885LPAR2 903/4885LPAR1 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.